Skip to main content

Dysfunctional Voiding

Dysfunctional voiding (DV) is inappropriate contraction or failure of relaxation of the external urethral sphincter and/or pelvic floor during voiding in a neurologically normal patient. The result is functional bladder outlet obstruction: a low-flow, often intermittent voiding pattern that may produce lower urinary tract symptoms, recurrent urinary tract infection, vesicoureteral reflux, incomplete emptying, or, in severe neglected cases, upper-tract deterioration.[1][2]

Definition and Terminology​

DV is reserved for neurologically normal individuals. The ICS defines it as an intermittent and/or fluctuating flow rate due to involuntary intermittent contractions of the periurethral striated muscle or pelvic floor during voiding.[23] An intermittent or fluctuating flow pattern raises suspicion for DV, but a staccato curve is neither specific nor required. Pelvic-floor EMG or video-urodynamics helps identify outlet activity during voiding.[2][23] DV is generally conceptualized as a learned or habitual pelvic-floor behavior rather than a structural lesion.[1][4][23]

The distinction to make is from detrusor-sphincter dyssynergia (DSD). DSD occurs in patients with neurologic disease such as spinal cord injury or multiple sclerosis and reflects loss of coordination between detrusor contraction and sphincter relaxation.[3] The International Continence Society (ICS) and International Children's Continence Society (ICCS) terminology separates non-neurogenic DV from neurogenic DSD even when the pressure-flow or EMG appearance seems superficially similar.[4][5]

TermMeaningPractical implication
Dysfunctional voidingPelvic-floor / external-sphincter activity during voiding in a neurologically normal patientFunctional outlet obstruction; treat with urotherapy, pelvic-floor retraining, and biofeedback
DSDInvoluntary sphincter contraction during detrusor contraction in neurologic diseaseNeurogenic outlet obstruction; manage within NLUTD risk framework
Poor relaxation of external sphincter / pelvic floorIncomplete relaxation without classic staccato pattern or high-pressure obstructionAdult female differential diagnosis; often overlaps clinically with DV
Primary bladder neck obstructionFailure of bladder-neck opening with quiet sphincter EMGSeparate diagnosis; often delayed flow onset and bladder-neck narrowing on video-UDS

Epidemiology​

Prevalence estimates remain imprecise because diagnostic criteria, referral populations, and testing methods vary widely across pediatric and adult female voiding dysfunction studies.[4][10]

In children, DV is one of the major functional daytime lower urinary tract disorders and is commonly associated with urgency, incontinence, constipation, recurrent UTI, and VUR.[1][5] Daytime incontinence of all subtypes affects roughly 7-10% of children aged 5-13 years; DV is one subtype, and a population prevalence for DV itself is not well established.[5] Girls are affected more often in many pediatric series, and the phenotype may persist into adulthood.[2][8]

In adult women referred for refractory LUTS or videourodynamics, DV is a frequent non-neurogenic diagnosis. Chen and Kuo identified DV in 10.5% of women undergoing video-urodynamic evaluation for LUTS, while another VUDS series of women with refractory LUTS found DV in 17.0%.[7][9] In a cross-sectional follow-up of females treated for childhood DV, 10 of 25 responders (40%) still had a staccato or interrupted flow pattern about 21 years later (versus 10.6% of controls), and the authors report daytime incontinence in 56% and UTI in 28%.[8] Only 25 of 123 eligible women participated, so these figures are approximate.[8]

In young men, EAU 2026 describes PBNO and dysfunctional voiding as the two most common voiding disorders at ages 18 to 50, with videourodynamic series in selected men reporting PBNO in up to 54% and dysfunctional voiding in up to 43%. Diagnosis rests on videourodynamics: intermittent external sphincter EMG activity during voiding without straining, brief closure of the membranous urethra on fluoroscopy, and a fluctuating flow curve on uroflowmetry in a private setting. EAU weakly recommends behavioral modification with biofeedback as first-line therapy and intermittent catheterization when that fails.[24] In the original series of 43 men unresponsive to alpha blockers, 35 were reported to have at least a 50% symptom decrease at 6 months.[32] For the young-man PBNO pathway, see Primary Bladder Neck Obstruction.[24]

Pathophysiology​

The central mechanism is failure of the external sphincter-pelvic floor complex to relax during micturition. During a detrusor contraction, the outlet should quiet and open; in DV, intermittent or sustained pelvic-floor activity narrows the functional outlet, producing elevated voiding pressures, staccato or interrupted flow, incomplete emptying, and post-void residual.[1][2]

Proposed drivers include:

  • Learned holding behavior. Pelvic-floor contraction becomes habitual.
  • Response to detrusor overactivity. Children may contract the pelvic floor to prevent urgency incontinence, then carry that behavior into voiding.
  • Voiding postponement. Chronic deferral promotes pelvic-floor hypertonicity and inefficient emptying.
  • Psychological and behavioral factors. Anxiety, toileting conflict, and behavioral comorbidity may contribute to persistence, especially in refractory pediatric cases.[1][4][5]

Detrusor overactivity is common. Adult female DV series report concurrent DO in a substantial proportion of patients.[4][7] In a pediatric VUDS cohort of 237 children with non-neurogenic voiding disorders, DO was present in 91% classified with DV.[2][11]

Bowel dysfunction is part of the same system. Constipation and impaired rectal emptying increase pelvic-floor guarding, worsen bladder sensation, and reduce the chance that urinary symptoms resolve unless treated concurrently.[2][5][12] A systematic review included 22 studies (12,281 children with functional constipation); the three studies measuring overall lower urinary tract symptoms reported prevalences of 37-64%, reinforcing why bowel treatment is addressed before or alongside bladder-directed therapy.[30]

Clinical Presentation​

Children​

Voiding symptoms include:

  • Staccato or intermittent urinary stream
  • Prolonged voiding time
  • Hesitancy or straining
  • Sensation of incomplete emptying
  • Elevated post-void residual

Storage and associated findings include:

  • Urgency, frequency, and daytime urinary incontinence
  • Nocturnal enuresis
  • Recurrent UTI
  • Constipation or fecal retention
  • VUR or hydronephrosis in more severe cases
  • Pelvic holding maneuvers and voiding postponement[1][2][5]

Pediatric Mimics​

Two patterns can be mistaken for DV in girls:

  • Vaginal voiding. Urine enters the vagina during micturition and drains after the child stands or walks, typically within minutes; labial adhesion or fusion may contribute. Directing the stream by voiding with the legs apart and leaning forward has been suggested. A urine specimen collected from vaginally drained urine can give a misleading positive culture.[26] A small-to-moderate leak immediately after voiding is typical, and some children also leak after a cough or sneeze.[28] A posture with hips abducted and a straight lumbar spine, plus a cough at the end of voiding to help clear urine from the vagina, are additional maneuvers alongside the legs-apart, forward-leaning posture above.[28]
  • Giggle incontinence. Sudden, involuntary, often complete bladder emptying occurs during or immediately after laughter, a distinct phenotype from the staccato DV pattern.[27] Biofeedback and methylphenidate have both been reported as treatment; in a one-year, non-randomized comparison of 38 children, complete response at 12 months was reported more often with biofeedback than with methylphenidate.[29]

Adults​

Adult DV often presents as mixed storage and voiding LUTS rather than a clean obstructive syndrome. In adult female VUDS series, common complaints include frequency, dysuria, urgency incontinence, hesitancy, weak stream, incomplete emptying, and recurrent UTI.[7][9]

Red Flags​

Hematuria, recurrent febrile UTI, hydronephrosis, high PVR, abnormal neurologic examination, prior pelvic surgery, radiation, suspected urethral stricture, or severe pain should trigger more complete evaluation before labeling symptoms as functional.

Diagnostic Evaluation​

Clinical Assessment​

Initial evaluation should include:

  • Detailed voiding history, including onset, stream pattern, postponement behavior, incontinence, UTIs, and prior instrumentation
  • Bowel history and constipation assessment
  • Voiding diary when symptoms are frequent or poorly characterized
  • Focused neurologic examination to exclude neurogenic disease
  • Pelvic, perineal, or genital examination when anatomy, prolapse, lichen sclerosus, urethral mass, or stricture is in the differential
  • Urinalysis and culture when infection is possible
  • PVR measurement[1][2][5]

Non-Invasive Urodynamics​

Uroflowmetry with pelvic-floor EMG is the core non-invasive diagnostic test.[2][5][6] EMG helps determine whether the pelvic floor is quiet or active during voiding.[2][5][6]

Characteristic findings:

TestDV patternWhy it matters
UroflowmetryStaccato or interrupted flow; sometimes prolonged low flowSuggests intermittent outlet closure during voiding
Pelvic-floor EMGActivity during voidingSupports pelvic-floor nonrelaxation; surface perianal EMG predominantly samples levator ani, not the external urethral sphincter[2]
PVR ultrasoundMay be elevatedQuantifies emptying failure and guides follow-up
Renal-bladder ultrasoundUsually normal in mild disease; may show hydronephrosis or bladder wall changes in severe diseaseScreens for upper-tract risk

Pediatric uroflow evaluation requires at least two representative voids of at least 50% expected bladder capacity, preferably three, with PVR measurement; EMG improves diagnostic confidence and helps separate DV from other non-neurogenic voiding disorders.[2][5][6]

EMG lag time can help distinguish diagnoses. A prolonged interval between pelvic-floor silence and flow onset suggests primary bladder neck dysfunction rather than DV; active EMG during flow supports DV.[6]

Invasive Urodynamics and Video-Urodynamics​

Invasive urodynamics is not required for every child with classic DV, but it is appropriate when symptoms are severe, refractory, anatomically confusing, associated with upper-tract changes, or being evaluated before irreversible outlet intervention.

In adults, video-urodynamics (VUDS) is often the most definitive study because it can show the level of functional narrowing during voiding and separate DV from primary bladder neck obstruction, urethral stricture, detrusor underactivity, prolapse-related kinking, and poor relaxation of the pelvic floor.[7][9][13]

Reported adult DV patterns include lower maximum flow, higher voiding detrusor pressure, larger PVR, reduced voiding efficiency, and a plateau-like detrusor contraction pattern on pressure-flow testing.[7][9][13] A plateau pattern occurred in 86% of women with DV or external-sphincter nonrelaxation in one retrospective cohort; the cohort included 40 women across diagnoses.[13] In women, a PdetQmax of 30 cmH2O or more helps separate DV from poor relaxation of the external sphincter (ROC AUC 0.93, one large retrospective video-urodynamic series cited by the EAU).[23]

Differential Diagnosis​

ConditionEMG during voidingFlow patternKey distinguishing feature
Dysfunctional voidingActiveStaccato or interruptedNeurologically normal; pelvic-floor activity during voiding
Detrusor-sphincter dyssynergiaActiveObstructed / intermittentNeurologic disease present
Primary bladder neck obstructionQuietDepressed, delayed, or plateau flowBladder neck fails to open; prolonged EMG lag time
Hinman syndrome (non-neurogenic neurogenic bladder)Usually activeObstructed, high residualSevere end of the dysfunctional-elimination spectrum with upper-tract damage, constipation and psychosocial stress; neurologic work-up is normal[22]
Fowler syndromeComplex repetitive discharges on sphincter EMGRetention, low flowYoung women with painless retention and a high-volume bladder; primary sphincter relaxation failure, not learned guarding[23]
Detrusor overactivity with urgency suppressionUsually quiet during true voidingVariableStorage-phase DO dominates; pelvic-floor guarding may coexist
Detrusor underactivityQuietLow flow, often prolongedLow-pressure poor emptying without outlet activation
Urethral stricture or meatal stenosisQuiet unless guardingLow or plateau flowAnatomic narrowing on exam, cystoscopy, calibration, RUG/VCUG, or VUDS
Prolapse-related obstructionQuiet or guardingPosition-dependent low flowObstruction improves with prolapse reduction
Poor relaxation of external sphincter / pelvic floorIncomplete relaxationLow-pressure low-flowAdult female overlap syndrome; less classic staccato high-pressure DV

Management​

Standard Urotherapy​

For children with daytime lower urinary tract conditions, standard urotherapy is the initial nonpharmacological treatment.[19] Core components include:

  • Education about bladder, bowel, and pelvic-floor coordination
  • Timed voiding every 2-3 hours while awake
  • Adequate daytime hydration
  • Relaxed voiding posture with feet supported
  • Avoidance of straining and hurried voiding
  • Constipation treatment with diet, bowel regimen, and stool-softening therapy when needed
  • Hygiene measures for recurrent UTI risk
  • Voiding diary review and family coaching in children[1][5][12][14]

Urotherapy plus abdominal and pelvic-floor retraining can normalize flow patterns and improve incontinence, nocturnal enuresis, UTIs, and constipation in many children.[12]

Biofeedback Pelvic-Floor Therapy​

Biofeedback is a commonly used addition for DV that persists despite standard urotherapy. In a randomized trial of 74 women with DV, 68 completed 12 weeks of treatment (34 per arm); biofeedback-assisted pelvic-floor training yielded higher mean Qmax (14.8 versus 12.8 mL/s), lower mean PVR (54.7 versus 65.7 mL), and lower median UDI-6 score (9 versus 12) than training alone.[33] EMG-guided or animated biofeedback teaches the patient to identify pelvic-floor activity and then relax during voiding.[1][2][15][16]

Typical programs use repeated supervised sessions over weeks to months, with home practice between visits. Goals include:

  • Quiet pelvic-floor EMG during voiding
  • Bell-shaped or less interrupted flow curve
  • Lower PVR
  • Reduced urgency and incontinence
  • Fewer UTIs
  • Improved confidence and reduced toileting avoidance

In one uncontrolled series of 31 women with DV, a 3-month biofeedback pelvic-floor muscle exercise program was followed by moderate or marked patient-reported improvement (GRA ≥2) in 25/31 (80.6%); recurrent UTI in the prior year predicted a poorer result, and flow rate, voided volume, voiding efficiency, total bladder capacity, and voiding time improved.[15] A 2025 meta-analysis of four small randomized trials (244 children overall) found greater flow-pattern normalization at 6 and 12 months, lower PVR at 6 months, and higher Qmax at 12 months; its enuresis analysis (43 children in three trials) found benefit at 12 months only.[16] A 2024 randomized-trial meta-analysis found no substantial improvement in daytime or nighttime incontinence.[34] For women with functional bladder outlet obstruction, EAU 2026 strongly recommends pelvic-floor muscle training aimed at relaxation; it rates evidence that biofeedback may improve symptoms as level 1b.[23]

Adjunctive pediatric physical-therapy approaches include diaphragmatic breathing, abdominal relaxation, and functional pelvic-floor exercises. A randomized trial using Swiss-ball pelvic-floor exercises plus urotherapy reported higher rates of normalized voiding pattern and disappearance of voiding-phase EMG activity than urotherapy alone.[17]

EAU guidance supports urotherapy and selected add-on biofeedback; controlled pediatric evidence is limited, and response rates come from individual series.[19] Specifically, EAU strongly recommends starting with the least invasive treatment and providing adequate bowel management when bladder-bowel dysfunction is present. After treatment failure, it weakly recommends re-evaluation that may include video-urodynamics, lumbosacral MRI, or cystoscopy.[19] It reports a 59% response when pelvic-floor muscle training is added to biofeedback in therapy-refractory children, and relapse in 20% within two years of an initial biofeedback response.[19]

Pharmacotherapy​

Drug classRoleCaveat
Alpha-blockersMay relax bladder-neck smooth muscle and lower outlet resistance in selected women with functional BOOUroselective agents are an off-label option ; discuss benefits and adverse effects; monitor blood pressure and dizziness[23]
BaclofenGABA-B agonist that relaxes the striated sphincter; oral 10 mg three times daily for 4 weeks in women with EMG-confirmed DVOff-label; somnolence, dizziness and nausea; evidence is a single crossover RCT (n = 60)[20]
Antimuscarinics / beta-3 agonistsTreat concurrent urgency, frequency, and DOCheck PVR and emptying safety before and after treatment
Bowel medicationsTreat constipation and fecal retentionOften essential to urinary improvement

In children with DV and urinary retention, a small non-randomized study (28 children, doxazosin versus biofeedback) found similar PVR reductions with either approach.[18] Alpha-blockers have been used as an adjunct or alternative to biofeedback. This is off-label, diagnosis-specific treatment; EAU notes that a pediatric randomized trial did not demonstrate benefit.[19] In adult women, the EAU 2026 guideline offers uroselective alpha-blockers off-label for functional bladder outlet obstruction , noting improvement from baseline but no proven advantage over placebo.[23] In a retrospective VUDS series, 28/54 women (51.9%) with DV whose chief complaint was voiding LUTS had an improvement of more than two points on the Patient Perception of Bladder Condition scale after one to three months of alpha-blocker treatment, with or without a skeletal muscle relaxant.[7]

The same guideline weakly recommends offering oral baclofen to women with BOO, particularly those with increased EMG activity and sustained detrusor contraction during voiding.[23] In a 60-woman placebo-controlled crossover trial, baclofen 10 mg three times daily for 4 weeks reduced voids per 24 hours and improved an EMG index of DV.[20][23]

Advanced and Refractory Therapies​

For refractory DV, options may include repeat biofeedback with a specialized pelvic-floor therapist, behavioral-health support when indicated, and intermittent catheterization for unsafe retention. In women with functional BOO, EAU 2026 weakly recommends intrasphincteric botulinum toxin and sacral nerve stimulation.[23] For refractory DV in young men, EAU describes sacral neuromodulation as experimental.[24] Evidence is limited and heterogeneous, so these should be individualized and usually managed in a functional urology or pediatric continence program.[1][4]

Botulinum toxin (off-label). Adult studies used 100 U onabotulinumtoxinA injected into the striated urethral sphincter; repeat injections were evaluated.[21][25] Reported adverse events include UTI, temporary need for intermittent catheterization, and increased incontinence. In a retrospective series of 95 patients with mixed neurogenic and non-neurogenic sphincter hyperactivity, 18 reported increased incontinence (6 stress, 12 urgency) after injection.[23][25] Small case series report symptomatic improvement and lower residuals. The placebo-controlled trial randomized 73 patients with DV or detrusor underactivity, and 62 completed one-month assessment. Patient Perception of Bladder Condition improvement of at least 2 points occurred in 14/38 (36.8%) given 100 U onabotulinumtoxinA versus 13/24 (54.2%) given saline overall, and in 7/16 (43.8%) versus 10/15 (66.7%) in the DV subgroup; neither comparison showed superiority, although detrusor voiding pressure fell only in the toxin-treated DV subgroup.[21] A retrospective review of 95 patients treated with 100 U onabotulinumtoxinA for voiding dysfunction from urethral sphincter hyperactivity reported satisfactory outcomes in 58 (61.1%) at 1 month; an open bladder neck during voiding was the only independent predictor of success (88% of successes versus 12% of failures), and therapeutic duration was longer in patients with non-neurogenic than neurogenic voiding dysfunction (9.55 versus 7.44 months).[25] In children, EAU describes intersphincteric injection as promising in therapy-refractory DV, ideally combined with urotherapy. A 2024 review of five cohorts (78 children) reported transient worsened incontinence, UTI, and gluteal numbness after injection.[19][31] Counsel about temporary retention before injecting.

Hinman syndrome is the severe, entrenched end of the spectrum. A French multicenter series of 31 children found that male sex, severe fecal retention, psychological disorder and delayed diagnosis predicted a poor outcome; intermittent catheterization, voiding retraining and anticholinergics each helped subsets.[22] Treat the bowel and psychosocial axes together with the bladder.

For DV without demonstrated anatomical obstruction or primary bladder neck obstruction, prioritize pelvic-floor relaxation rather than outlet surgery.[23] Incising a structurally normal outlet in a patient with active pelvic-floor obstruction risks trading obstruction for incontinence without addressing the behavior.

Follow-Up and Prognosis​

Follow-up should track symptoms and objective emptying:

  • Voiding diary and incontinence episodes
  • UTI frequency
  • Constipation control
  • Uroflow pattern
  • PVR
  • Renal-bladder ultrasound when upper-tract risk, VUR, recurrent febrile UTI, or high residuals are present
  • Arrange transition to adult urological care for adolescents with persistent daytime LUT conditions [19]

Most children improve with urotherapy and biofeedback, but DV can persist; the Cochrane review found little reliable evidence to rank conservative interventions for functional daytime incontinence.[14] Long-term female transition data show that childhood DV may carry into adulthood with ongoing incontinence, recurrent UTI, and quality-of-life impact.[8] In a retrospective series of 31 adult women, recurrent UTI in the preceding year was associated with poorer patient-reported response (Global Response Assessment ≥2) after three months of biofeedback.[15] A small transition survey documented persistent adult symptoms after childhood DV.[8]

Special Considerations​

Vesicoureteral Reflux​

VUR is common in children with DV and may improve when voiding-phase pelvic-floor obstruction is treated. Biofeedback-directed normalization of pelvic-floor relaxation can reduce voiding pressure and may support spontaneous VUR resolution in selected patients.[2][11][16]

Bowel Dysfunction​

Constipation must be treated as part of the urinary disorder. A child with fecal retention and DV is unlikely to normalize urinary symptoms if bowel mechanics remain unchanged.[5][12]

Psychological Comorbidity​

They identify a treatment axis: toileting routines, anxiety, family conflict around voiding, trauma history, ADHD, and school bathroom avoidance can all perpetuate pelvic-floor guarding.[4][5]

Surgical Planning​

Before urethral reconstruction, sling revision, prolapse repair, BPH surgery, bladder-neck incision, or continence surgery, unexplained low flow and elevated PVR should be sorted into anatomic obstruction, detrusor underactivity, neurogenic dysfunction, primary bladder neck obstruction, and DV. A functional obstruction missed preoperatively can look like surgical failure afterward.

References​

1. Bauer A. "Dysfunctional voiding: update on evaluation and treatment." Current Opinion in Pediatrics. 2021;33(2):235-242. doi:10.1097/MOP.0000000000000980

2. Clothier JC, Wright AJ. "Dysfunctional voiding: the importance of non-invasive urodynamics in diagnosis and treatment." Pediatric Nephrology. 2018;33(3):381-394. doi:10.1007/s00467-017-3679-3

3. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: diagnosis and evaluation." The Journal of Urology. 2021;206(5):1097-1105. doi:10.1097/JU.0000000000002235

4. Tarcan T, von Gontard A, Apostolidis A, Mosiello G, Abrams P. "Can we improve our management of dysfunctional voiding in children and adults: International Consultation on Incontinence Research Society; ICI-RS 2018?" Neurourology and Urodynamics. 2019;38 Suppl 5:S82-S89. doi:10.1002/nau.24088

5. Nieuwhof-Leppink AJ, Schroeder RPJ, van de Putte EM, de Jong TPVM, Schappin R. "Daytime urinary incontinence in children and adolescents." The Lancet Child & Adolescent Health. 2019;3(7):492-501. doi:10.1016/S2352-4642(19)30113-0

6. Van Batavia JP, Combs AJ, Hyun G, et al. "Simplifying the diagnosis of 4 common voiding conditions using uroflow/electromyography, electromyography lag time and voiding history." The Journal of Urology. 2011;186(4 Suppl):1721-1726. doi:10.1016/j.juro.2011.04.020

7. Chen YC, Kuo HC. "Clinical and video urodynamic characteristics of adult women with dysfunctional voiding." Journal of the Formosan Medical Association. 2014;113(3):161-165. doi:10.1016/j.jfma.2012.04.008

8. van Geen FJ, van de Wetering EHM, Nieuwhof-Leppink AJ, Klijn AJ, de Kort LMO. "Dysfunctional voiding: exploring disease transition from childhood to adulthood." Urology. 2023;177:60-64. doi:10.1016/j.urology.2023.03.018

9. Peng CH, Chen SF, Kuo HC. "Videourodynamic analysis of the urethral sphincter overactivity and the poor relaxing pelvic floor muscles in women with voiding dysfunction." Neurourology and Urodynamics. 2017;36(8):2169-2175. doi:10.1002/nau.23263

10. Sinha A, Tuttle B, Weidner A. "Non-neurogenic voiding dysfunction in pediatric patients and female adults: review of current clinical trials." Obstetrical & Gynecological Survey. 2026;81(1):29-38. doi:10.1097/OGX.0000000000001467

11. Glassberg KI, Combs AJ, Horowitz M. "Nonneurogenic voiding disorders in children and adolescents: clinical and videourodynamic findings in 4 specific conditions." The Journal of Urology. 2010;184(5):2123-2127. doi:10.1016/j.juro.2010.07.011

12. Zivkovic V, Lazovic M, Vlajkovic M, et al. "Diaphragmatic breathing exercises and pelvic floor retraining in children with dysfunctional voiding." European Journal of Physical and Rehabilitation Medicine. 2012;48(3):413-421. PMID 22669134

13. Agarwal MM, Sharma S, Jain S, et al. "Can urodynamic diagnosis of dysfunctional voiding/external sphincter nonrelaxation be made on two-channel pressure-flow study without video-urodynamics, electromyography, or urethral pressure profilometry? Plateau detrusor pattern in perspective." Neurourology and Urodynamics. 2022;41(4):935-944. doi:10.1002/nau.24897

14. Buckley BS, Sanders CD, Spineli L, Deng Q, Kwong JS. "Conservative interventions for treating functional daytime urinary incontinence in children." Cochrane Database of Systematic Reviews. 2019;9:CD012367. doi:10.1002/14651858.CD012367.pub2

15. Chiang CH, Jiang YH, Kuo HC. "Therapeutic efficacy of biofeedback pelvic floor muscle exercise in women with dysfunctional voiding." Scientific Reports. 2021;11:13757. doi:10.1038/s41598-021-93283-9

16. Passos CL, Souza M, Correa Leite MT, et al. "Efficacy of electromyographic biofeedback for dysfunctional voiding in children and adolescents: a systematic review and meta-analysis of randomized trials." Urology. 2025;206:114-120. doi:10.1016/j.urology.2025.08.046

17. Ladi Seyedian SS, Sharifi-Rad L, Ebadi M, Kajbafzadeh AM. "Combined functional pelvic floor muscle exercises with Swiss ball and urotherapy for management of dysfunctional voiding in children: a randomized clinical trial." European Journal of Pediatrics. 2014;173(10):1347-1353. doi:10.1007/s00431-014-2336-0

18. Yucel S, Akkaya E, Guntekin E, et al. "Can alpha-blocker therapy be an alternative to biofeedback for dysfunctional voiding and urinary retention? A prospective study." The Journal of Urology. 2005;174(4 Pt 2):1612-1615. doi:10.1097/01.ju.0000179241.99381.5e

19. European Association of Urology. EAU Guidelines on Paediatric Urology: Daytime Lower Urinary Tract Conditions. 2026. Guideline.

20. Xu D, Qu C, Meng H, et al. "Dysfunctional voiding confirmed by transdermal perineal electromyography, and its effective treatment with baclofen in women with lower urinary tract symptoms: a randomized double-blind placebo-controlled crossover trial." BJU International. 2007;100(3):588-592. doi:10.1111/j.1464-410X.2007.06987.x

21. Jiang YH, Wang CC, Kuo HC. "OnabotulinumtoxinA urethral sphincter injection as treatment for non-neurogenic voiding dysfunction: a randomized, double-blind, placebo-controlled study." Scientific Reports. 2016;6:38905. doi:10.1038/srep38905

22. Claudon P, Fotso-Kamdem A, Aubert D. "The non-neurogenic neurogenic bladder (Hinman's syndrome) in children: prognostic criteria based on a 31-case multicentric study [in French]." Progrès en Urologie. 2010;20(4):292-300. doi:10.1016/j.purol.2009.09.034

23. European Association of Urology. EAU Guidelines on Management of Non-neurogenic Female LUTS (limited update). March 2026. Guideline.

24. European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male LUTS. 2026 (March update). Official full guideline. See section 5.8.

25. Jiang YH, Chen SF, Jhang JF, Kuo HC. "Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity." Neurourology and Urodynamics. 2018;37(8):2651-2657. doi:10.1002/nau.23714

26. Bernasconi M, Borsari A, Garzoni L, Siegenthaler G, Bianchetti MG, Rizzi M. "Vaginal voiding: a common cause of daytime urinary leakage in girls." Journal of Pediatric and Adolescent Gynecology. 2009;22(6):347-350. doi:10.1016/j.jpag.2008.07.017

27. Logan BL, Blais S. "Giggle incontinence: evolution of concept and treatment." Journal of Pediatric Urology. 2017;13(5):430-435. doi:10.1016/j.jpurol.2017.04.021

28. Mattsson S, Gladh G. "Urethrovaginal reflux--a common cause of daytime incontinence in girls." Pediatrics. 2003;111(1):136-9. doi:10.1542/peds.111.1.136

29. Hacıislamoğlu A, Ekşi M, Özlü DN, et al. "Evaluation of the efficacies of methylphenidate and biofeedback treatments in giggle incontinence: One-year follow-up study." J Pediatr Urol. 2021;17(5):646.e1-646.e5. doi:10.1016/j.jpurol.2021.07.015

30. van Summeren JJGT, Holtman GA, van Ommeren SC, Kollen BJ, Dekker JH, Berger MY. "Bladder Symptoms in Children With Functional Constipation: A Systematic Review." J Pediatr Gastroenterol Nutr. 2018;67(5):552-560. doi:10.1097/MPG.0000000000002138

31. Hoelscher SAA, de Angst IB, Buijnsters ZA, et al. "The effect of botulinum toxin A in children with non-neurogenic therapy-refractory dysfunctional voiding - A systematic review." J Pediatr Urol. 2024;20(2):211-218. doi:10.1016/j.jpurol.2023.10.034

32. Kaplan SA, Santarosa RP, D’Alisera PM, et al. "Pseudodyssynergia (Contraction of the External Sphincter During Voiding) Misdiagnosed as Chronic Nonbacterial Prostatitis and the Role of Biofeedback as a Therapeutic Option." J Urol. 1997;157(6):2234-2237. doi:10.1016/S0022-5347(01)64727-X

33. Sam E, Cinislioglu AE, Yilmazel FK, Demirdogen SO, Yilmaz AH, Karabulut I. "Is biofeedback-assisted pelvic floor muscle training superior to pelvic floor muscle training alone in the treatment of dysfunctional voiding in women? A prospective randomized study." Int Braz J Urol. 2022;48(3):501-511. doi:10.1590/S1677-5538.IBJU.2021.0687

34. Li F, Feng L, Yang Y, Ma X, Kang T, Huang W. "The effect of biofeedback on nonneurological dysfunctional voiding in children: A meta-analysis and systematic review." J Pediatr Urol. 2024;20(4):565-580. doi:10.1016/j.jpurol.2024.06.042